Breaking News, Financial News

Financial Report: Johnson & Johnson

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 1Q Revenues: $15 billion (+16%) 1Q Earnings: $2.6 billion (-22%) Comments: Worldwide Pharmaceutical sales were $6.2 billion in the quarter, up 11%. Sales growth reflects the strong performance of Topamax, Levaquin, and antipsychotic franchise, which includes Risperdal, Risperdal Consta and Invega. Earnings in the quarter reflect an in-process R&D charge of $807 million associated with the acquisition of Conor Medsystems, Inc....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters